FAQ #1 –
How should low VAF variants be interpreted?
Low VAFs often suggest subclonal populations that might not be targeted by current therapies, or they can represent early, emergent resistance mutations
FAQ #2 –
What are actionable mutations in NGS reports?
Actionable mutations in NGS reports are specific tumor DNA alterations that, when identified, predict a patient’s response to a targeted therapy
FAQ #3 –
How are VUS reported and interpreted?
A Variant of Uncertain Significance (VUS) is reported when genetic testing identifies a DNA change, but insufficient or conflicting evidence exists to classify it as clearly disease-causing or benign. These variants, often found in 30% of hereditary cancer panels, are generally considered inconclusive, and should not be used to guide clinical management or treatment
FAQ #4 –
How should an NGS report be read?
Your Dr is trained to read & interpret an NGS report. An NGS (Next-Generation Sequencing) report should be read by first reviewing the patient and sample details, then focusing on the executive summary to identify actionable genetic variants
FAQ #5 –
What is NGS?
NGS enables scientists and researchers to perform high-throughput sequencing of patient DNA samples, often to identify genetic variation associated with diseases